What is Anavex Life Sciences Corporation Annual Net Profit?

Anavex Life Sciences Corporation Annual Net Profit rose 9.48% in the last year to $43 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

What is Anavex Life Sciences Corporation Price to Earning Ratio?

Anavex Life Sciences Corporation Price to Earning Ratio is -15.7, which is negative.

What is Anavex Life Sciences Corporation Stock Price?

Anavex Life Sciences Corporation Stock Price rose 68.57% and outperformed its sector by 62.11% in the past year.

What is Anavex Life Sciences Corporation Quarterly Net profit?

Anavex Life Sciences Corporation Quarterly Net profit fell 40.47% YoY to $12.11 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

What is Anavex Life Sciences Corporation Return on Equity(ROE)?

Anavex Life Sciences Corporation Return on Equity(ROE) for the last financial year was -32.81%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Anavex Life Sciences Corporation Mutual Fund Holding?

Anavex Life Sciences Corporation Mutual Fund Holding decreased by 0.25% in the last quarter to 25.61.

What is Anavex Life Sciences Corporation Promoter Share Holding?

Anavex Life Sciences Corporation Promoter Share Holding stayed the same in the most recent quarter at 4.41%.

What is Anavex Life Sciences Corporation Institutional Holding?

Anavex Life Sciences Corporation Institutional Holding increased by 2.86% in the last quarter to 34.73.

How is the Anavex Life Sciences Corporation today?

The Anavex Life Sciences Corporation today is trading in the down by -1.61% at 8.58.

How has Anavex Life Sciences Corporation performed historically?

The Anavex Life Sciences Corporation is currently trading down -1.61% on an intraday basis in the past week the index fell -11.91%. The index has been down -22.28% in the past quarter and rose 68.57% in the past year. You can view this in the overview section.

Anavex Life Sciences Corporation XNAS: AVXL

Anavex Life Sciences Corporation Live Share Price Today, Share Analysis and Chart

Name: Anavex Life Sciences Corporation: Is Infosys Ltd. worth buying?
Item: Anavex Life Sciences Corporation
Rating: 1.55700
Author: Trendlyne DVM scores

Download real time

8.58 -0.14 (-1.61%)

40.58% Fall from 52W High

1.4M XNAS Volume

XNAS 31 Mar, 2025 4:00 PM (EDT)

Anavex Life Sciences Corpo... Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	729.9
PE TTM Negative PE TTM Unavailable in chosen country	-15.7
PEG TTM High in industry Unavailable in chosen country	2
Price to Book High in industry Unavailable in chosen country	6.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	34.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-40.5
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-7.7
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-29.3
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-32.8
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-29.7

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

3.0 / 100

Technically Neutral

59.3 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Anavex Life Sciences Corpo... Stock Price Analysis

Day Price Range -1.6% 1 Day return Unavailable in chosen country	8.6 (LTP) 8.48.8 LowHigh
Week Price Range -11.9% 1 Week return Unavailable in chosen country	8.6 (LTP) 8.410 LowHigh
Month Price Range 9.3% 1 Month return Unavailable in chosen country	8.6 (LTP) 7.710.2 LowHigh
52 Week Price Range 68.6% 1 Year return Unavailable in chosen country	8.6 (LTP) 3.214.4 LowHigh

View full Share Price History

Anavex Life Sciences Corpo... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Anavex Life Sciences Corpo... Stock Analysis

Anavex Life Sciences Corpo... stock analysis with key metrics, changes, and trends.

Anavex Life Sciences Corpo... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$43 M	9.48%	positive	Annual Net Profit rose 9.48% in the last year to $43 M. Its sector's average net profit growth for the last fiscal year was -32.42%.
Price to Earning Ratio	-15.7	-	negative	Price to Earning Ratio is -15.7, which is negative.
Stock Price	$8.58	68.57%	positive	Stock Price rose 68.57% and outperformed its sector by 62.11% in the past year.
Quarterly Net profit	$12.11 M	40.47%	negative	Quarterly Net profit fell 40.47% YoY to $12.11 M. Its sector's average net profit growth YoY for the quarter was -47.39%.
Return on Equity(ROE)	-32.81 %	-32.81%	negative	Return on Equity(ROE) for the last financial year was -32.81%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	25.61 %	-0.25%	negative	Mutual Fund Holding decreased by 0.25% in the last quarter to 25.61.
Promoter Share Holding	4.41 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 4.41%.
Institutional Holding	34.73 %	2.86%	positive	Institutional Holding increased by 2.86% in the last quarter to 34.73.

VIEW LESS

Loading data..

Anavex Life Sciences Corporation - Company Profile

What does Anavex Life Sciences Corporation do?

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Corporation Management structure

All Gross Remunerations are in USD

Dr. Christopher U. Missling, PhD

Director, President, Chief Executive Officer and Secretary

2024

Gross Remuneration

Year

Ms. Sandra Boenisch, C.G.A.,C.P.A.

Principal Financial Officer, Principal Accounting Officer and Treasurer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Anavex Life Sciences Corporation Live Share Price Today, Share Analysis and Chart

40.58% Fall from 52W High

Anavex Life Sciences Corpo... Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Anavex Life Sciences Corpo... Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Anavex Life Sciences Corpo... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Anavex Life Sciences Corpo... Stock Analysis

Anavex Life Sciences Corpo... stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 9.48% in the last year to $43 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio is -15.7, which is negative.

Stock Price rose 68.57% and outperformed its sector by 62.11% in the past year.

Quarterly Net profit fell 40.47% YoY to $12.11 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Return on Equity(ROE) for the last financial year was -32.81%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.25% in the last quarter to 25.61.

Promoter Share Holding stayed the same in the most recent quarter at 4.41%.

Institutional Holding increased by 2.86% in the last quarter to 34.73.

Anavex Life Sciences Corporation - Company Profile

What does Anavex Life Sciences Corporation do?

Anavex Life Sciences Corporation Management structure

Dr. Christopher U. Missling, PhD

Director, President, Chief Executive Officer and Secretary

Ms. Sandra Boenisch, C.G.A.,C.P.A.

Principal Financial Officer, Principal Accounting Officer and Treasurer

Anavex Life Sciences Corporation Board of directors

Mr. Athanasios Skarpelos

Independent Director

Dr. Christopher U. Missling, PhD

Director, President, Chief Executive Officer and S

Dr. Steffen Thomas, PhD

Independent Director

Dr. Peter Donhauser, D.O.

Independent Director

Dr. Claus van der Velden, PhD

Independent Director

Dr. Jiong Ma, PhD

Chairman of the Board

Anavex Life Sciences Corporation FAQ

How is Anavex Life Sciences Corporation today?

Anavex Life Sciences Corporation today is trading in the red, and is down by -1.61% at 8.58.

How has Anavex Life Sciences Corporation performed historically?

Anavex Life Sciences Corporation is currently trading down -1.61% on an intraday basis. In the past week the stock fell -11.91%. stock has been down -22.28% in the past quarter and rose 68.57% in the past year. You can view this in the overview section.